Cholestatic Liver Disease after Rituximab and Adalimumab and the Possible Role of Cross-Reacting Antibodies to Fab 2 Fragments

Cholestatic Liver Disease after Rituximab and Adalimumab and the Possible Role of Cross-Reacting Antibodies to Fab 2 Fragments

Bibliographic Details
Main Authors: Latus, Joerg, Klein, Reinhild, Koetter, Ina, Schwab, Matthias, Fritz, Peter, Kimmel, Martin, Alscher, M. Dominik, Braun, Niko
Format: Online
Language:English
Published: Public Library of Science 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823999/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823999/

Similar Items